[EN] SUBSTITUTED OCTAHYDROPYRROLO[1,2-A]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS [FR] OCTAHYDROPYRROLO[1,2-A]PYRAZINE SULFONAMIDES SUBSTITUÉS À TITRE D'INHIBITEURS DES CANAUX CALCIQUES
[EN] SUBSTITUTED OCTAHYDROPYRROLO[1,2-A]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS [FR] OCTAHYDROPYRROLO[1,2-A]PYRAZINE SULFONAMIDES SUBSTITUÉS À TITRE D'INHIBITEURS DES CANAUX CALCIQUES
Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers
申请人:AbbVie Inc.
公开号:US08669255B2
公开(公告)日:2014-03-11
The present application relates to: (a) compounds of Formula (I):
and salts thereof, wherein Z1, Z2, Z3, Z4, R1, R2, and R3 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.
SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS
申请人:ABBVie Inc.
公开号:US20130085141A1
公开(公告)日:2013-04-04
The present application relates to: (a) compounds of Formula (I):
and salts thereof, wherein Z′, Z″, L
2
, G
2
, R
1
, and R
2
are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel blockers.
SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS
申请人:AbbVie Inc.
公开号:US20130085142A1
公开(公告)日:2013-04-04
The present application relates to: (a) compounds of Formula (I):
and salts thereof, wherein Z
1
, Z
2
, Z
3
, Z
4
, R
1
, R
2
, and R
3
are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.
Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
申请人:AbbVie Inc.
公开号:US08648074B2
公开(公告)日:2014-02-11
The present application relates to: (a) compounds of Formula (I):
and salts thereof, wherein Z′, Z″, L2, G2, R1, and R2 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel blockers.